In draft guidance, NICE has recommended ledipasvir-sofosbuvir (Harvoni, Gilead Sciences) as a treatment option for some adults with genotype 1 or 4 chronic hepatitis C. It is not recommended (in combination with ribavirin) for treatment of GT3.
There have been lots of Hep C appraisals in the last couple of years; boceprevir, telaprevir, simeprevir, sofosbuvir. An interesting difference with this appraisal is with the potential use of alternative treatment durations recommended by the EMA. The use of these alternative durations has a substantial impact upon the cost-effectiveness of LDV/SOF; shortened treatment durations were a lot more cost-effective.
The ERG report was produced by SHARR-TAG, with the HEDS authors being Praveen Thokala, Emma Simpson, Paul Tappenden, John Stevens and Kath Dickinson.
